NCT01861834Approved For Marketing不适用
A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 2
研究概览
简要总结
To provide children dependent on total parenteral nutrition with Omegaven®, a fish oil-based intravenous lipid emulsion that may be less hepatotoxic than conventional, vegetable oil-based intravenous lipid emulsions, and that may therefore reduce the need for liver transplantation.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Months 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The targeted population for enrollment is the cohort of patients with TPN-dependent short bowel syndrome, defined as any pediatric patient who, following abdominal surgery, has a residual small bowel length less than 25% of that predicted for gestational age or requires postoperative TPN for more than 42 days because of gastrointestinal intolerance and who has developed TPN-associated liver disease sufficient to pose a significant risk for progression to liver failure based on the following criteria:
- •Total serum bilirubin concentration greater than 3 mg/dL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.
- •PLUS EITHER:
- •Platelet count less than 200,000/μL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.
- •Serum albumin concentration less than 3.2 mg/dL after a total duration of TPN greater than 2 months in the absence of a proven episode of bacteremia within the preceding 3 weeks.
- •Patients with coagulopathy due to parenteral nutrition-associated liver disease (INR > 1.2) will be potential candidates for enrollment, because patients with an elevated INR exceeding 2 have demonstrated resolution of coagulopathy after treatment with Omegaven®. Similarly, patients with hyperlipidemia will be potential candidates for enrollment.
- •Alternatively, patients currently receiving Omegaven that was initiated at another center because of intestinal failure with liver disease that do not need to meet the lab criteria listed above. The subject may continue Omegaven under this protocol at the discretion of the Principle Investigator.
排除标准
- •Patients with a history of the following will be excluded from enrollment in this protocol:
- •Allergy to fish or egg protein.
- •Liver disease proven or suspected to be caused by a process other than TPN-dependent short bowel syndrome, including but not limited to hepatitis C, hepatitis B, cystic fibrosis, biliary atresia, Alagille syndrome, familial intrahepatic cholestasis, and alpha-1-antitrypsin deficiency.
- •Refusal of third party providers to reimburse hospital for the cost of Omegaven®.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Omegaven as Alternative Parenteral Fat NutritionCholestasisCholestasis of Parenteral NutritionNCT03662282University of South Florida2
Approved For Marketing
不适用
Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver DiseaseCholestasisShort Bowel SyndromeNCT01297933Children's Hospital of Philadelphia
撤回
不适用
Compassionate Use of Omegaven IV Fat EmulsionTotal Parenteral Nutrition-induced CholestasisNCT01323907Sivan Kinberg
No Longer Available
不适用
Omegaven Expanded Access ProtocolParenteral Nutrition Associated Liver DiseaseNCT02121769St. Luke's Health System, Boise, Idaho
已完成
2 期
Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver DiseaseParenteral Nutrition-related HepatitisNCT04697888Children's Mercy Hospital Kansas City2